GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
